Advances in the treatment of moderate-to-severe plaque psoriasis

American Journal of Health-System Pharmacy

Volumn 68, Issue 9, 2011, Pages 795-806

  Herrier, Richard N ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acitretin; Adalimumab; Antibodies; Antiinflammatory agents; Biologicals; Cyclosporine; Dosage schedule; Etanercept; Immunosuppressive agents; Infliximab; Keratolytic agents; Mechanism of action; Methotrexate; Phototherapy; Psoriasis; Site of action; Topical preparations; Toxicity; Ustekinumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; APREMILAST; BRIAKINUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; PLACEBO; PSORALEN; SIPLIZUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

CHILL; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG SAFETY; DYSPNEA; FLUSHING; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; NEUROLOGIC DISEASE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; REVIEW; SIDE EFFECT; T LYMPHOCYTE; ULTRAVIOLET B RADIATION;

EID: 79956040242     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100227     Document Type: Review

References (106)

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Psoriasis. www.niams.nih.gov/Health-Info/Psoriasis/default.asp (accessed 2011 Jan 14).
2. Thomas V, Ynag FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005; 53:347-51.
3. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370:263-71. (Pubitemid 47069537)
4. Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part 1): clinical update on antitumor necrosis factor agents. J Drugs Dermatol. 2009; 8:147-54.
5. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496-509.
6. Menter A, Griffiths C. Current and future management. Lancet. 2007; 370:272-84.
7. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? Facts and controversies. Clin Dermatol. 2010; 28:67-72.
8. Parsier DM, Bagel J, Gelfand JM et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007; 143:239-42. (Pubitemid 46294591)
9. Spuls PI, Lecluse LL, Poulsen ML et al. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol. 2010; 130:933-43.
10. Schafer I, Hacker J, Rustenbach SJ et al. Concordance of the Psoriasis Area Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010; 20:62-7.
11. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005; 152:954-60. (Pubitemid 40704936)
12. Krueger GG, Langley RG, Finlay AY et al. Patient reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005; 153:1190-9.
13. Daudén E, Griffiths CE, Ortonne JP et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009; 23: 1374-82.
14. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004; 150:317-26. (Pubitemid 38352471)
15. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000; 356:385-90. (Pubitemid 30487495)
16. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept in the treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum. 2004; 50:2264-72. (Pubitemid 38924405)
17. Sterry W, Otonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010; 340:c147.
18. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum. 2005; 52:3279-89.
19. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009; 60:643-59.
20. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58:826-50. (Pubitemid 351509656)
21. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61:451-85.
22. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23(suppl 2):1-70. [Erratum, J Eur Acad Dermatol Venereol. 2010; 24:117-8.]
23. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med. 1999; 189:711-8. (Pubitemid 29193372)
24. Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed. 2005; 21:260-6. (Pubitemid 41387341)
25. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001; 26:343-50. (Pubitemid 34204349)
26. Matz H. Phototherapy for psoriasis: what to choose and how to use: facts and controversies. Clin Dermatol. 2010; 28:73-80.
27. Sivanesan SP, Gattu S, Hong J et al. Randomized, double-blind, placebocontrolled study of oral psoralen plus ultraviolet A for the treatment of plaquetype psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol. 2009; 61:793-8.
28. Heydendael V, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate to severe chronic plaque psoriasis. N Engl J Med. 2003; 349:658-64.
29. Kalb RE, Strober B, Weinstein G et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009; 60:824-37.
30. Saurat JH, Singl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158:558-66. (Pubitemid 351239154)
31. Saurat JH, Guerin A, Yu AP et al. High prevalence of potential drug-drug interactions in psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010; 220:128-37.
32. Lam J, Polifka JE, Dohil MA. Safety of dermatological drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008; 59:295-315.
33. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001; 357:1842-7. (Pubitemid 32539117)
34. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004; 51:534-42. (Pubitemid 39278071)
35. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366:1367-74. (Pubitemid 41443403)
36. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2007; 56:e1-15.
37. Gordon K, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006; 55:598-606. (Pubitemid 44436647)
38. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58:106-15. (Pubitemid 350298146)
39. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349:2014-22. (Pubitemid 37448924)
40. Papp KA, Tyring M, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, ef- ficacy, and effect of dose reduction. Br J Dermatol. 2005; 152:1304-12. (Pubitemid 40933433)
41. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006; 367:29-35. (Pubitemid 43038667)
42. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139:1627-32. (Pubitemid 37523083)
43. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007; 143:719-26. (Pubitemid 46955730)
44. Griffiths C, Strober B, van de Kerhof P et al. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010; 362:118-28.
45. Ellis CN, Kreuger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001; 345:248-55. (Pubitemid 32695064)
46. Krueger GG, Papp KA, Stough DB et al. A randomized, double-blind, placebocontrolled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002; 47:821-33. (Pubitemid 35403039)
47. Lebwohl M, Christophers E, Langely R et al. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003; 139:719-27. (Pubitemid 36705938)
48. Gribetz CH, Blum R, Brady C et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2005; 53:73-5. (Pubitemid 40826697)
49. Roberts JL, Ortonne JP, Tan JK et al. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2010; 62:969-78.
50. Gordon KB, Vaishnaw AK, O'Gorman J et al. Treatment of psoriasis with alef acept: correlation of clinical improvement with reductions in memory T-cell counts. Arch Dermatol. 2003; 139:1563-70. (Pubitemid 37523074)
51. Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe psoriasis (part 2): clinical update on T-cell modulators and investigational agents. J Drugs Dermatol. 2009; 8:230-8.
52. Kuehn B. Efalizumab withdrawn. JAMA. 2009; 301:2085. News.
53. Tan CS, Koralink IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010; 9:425-37.
54. Bagel J. Evaluating the interleukin antibodies. www.bmctoday.net/ practicaldermatology/pdfs/PD0809-13.pdf (accessed 2011 Jan 28).
55. Elliot M, Benson J, Blank M et al. Ustekinumab: lessons learned from targeting interleukin 12/23p40 in immune mediated diseases. Ann N Y Acad Sci. 2009; 1182:97-110.
56. Leonardi CI, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX-1). Lancet. 2008; 371:1665-74. (Pubitemid 351671883)
57. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX-2). Lancet. 2008; 371:1675-84. (Pubitemid 351671884)
58. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human monoclonal antibody, for psoriatic arthritis: a randomised, double-blind, placebocontrolled crossover trial. Lancet. 2009; 373:633-40.
59. Stelara (ustekinumab) prescribing information. Horsham, PA: Centocor Ortho Biotech Inc.; 2009 Sep.
60. Hinchey J, Chaves C, Appigani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334:494-500. (Pubitemid 26067737)
61. Mazzotta A, Esposito M, Costanzo A et al. Efficacy and safety of etanercept in psoriasis after switching from other treatments. An observational study. Am J Clin Dermatol. 2009; 10:319-24.
62. Yamaguchi P, Mau N. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol. 2009; 61:159-60.
63. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007; 57:120-5. (Pubitemid 46899280)
64. Papoutrsaki M, Chimenti MS, Costanzo A et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007; 57:269-75. (Pubitemid 47048857)
65. Lecluse L, de Groot M, Bos JD et al. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol. 2009; 161:948-51.
66. Alwawi EA, Krulig E, Gordon KB. Longterm efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009; 22:431-40.
67. Duffin KC, Woodcock J, Kreuger GG. Genetic variations associated with psoriasis and psoriatic arthritis found by genome wide association. Dermatol Ther. 2010; 23:101-13.
68. Suarez-Farinas M, Shah KJ, Haider AS et al. Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to alefacept. BMC Dermatol. 2010; 10:1-8.
69. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117:244-79.
70. Sitzo S, Bansback N, Feldman SR et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009; 160:1264-72.
71. Ferrandiz C, Carrascosa JM, Boada A. A new era of management of psoriasis? The biologics: facts and controversies. Clin Dermatol. 2010; 28:81-7.
72. Lecluse L, Driessen R, Spuls PI et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010; 146:127-32.
73. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis. Maintaining efficacy and safety for the long haul. Arch Dermatol. 2010; 146:186-8.
74. Aikawa NE, deCarvalho JF, Silva CA et al. Immunogenicity of anti-TNF agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010; 38:82-9.
75. Pink AE, Fonia A, Allen MH et al. Antinuclear antibodies associate with loss of response to antitumor necrosis factoralpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010; 162:780-5.
76. Bendtzen K, Ainsworth M, Steeinholdt C et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumor necrosis factoralpha antibodies. Scand J Gastroenterol. 2009; 44:774-81.
77. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66:921-6. (Pubitemid 46999794)
78. Wolbink GJ, Vis M, Lems W et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54:711-5.
79. DeVries MK, Wolbink GJ, Stapel SO et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab antibodies formation. Ann Rheum Dis. 2007; 66:1252-4. (Pubitemid 47309746)
80. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009; 60:2541-2.
81. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010; 146:186-8.
82. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007; 56:598-603. (Pubitemid 46400183)
83. Jensen P, Skov L, Zachariae C. Systemic combination treatment for psoriasis: a review. Acta Derm Venereol. 2010; 90:341-9.
84. Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010; 22:138-42.
85. Smith E, Riddle C, Menter A et al. Combining retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008; 47:514-8. (Pubitemid 351560322)
86. Dalaker M, Bonesronning JH. Long term maintenance treatment in moderate to severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine. J Eur Acad Dermatol Venereol. 2009; 23:277-82.
87. Lebwohl M. Combining new biologic agents with our current armamentarium. J Am Acad Dermatol. 2003; 49(suppl):S118-24.
88. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumor necrosis factor alpha inhibitor therapy: a report of 3 cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009; 160:8-15.
89. Laffitte E, Janssens JP, Roux-Lombard P et al. Tuberculosis screening in patients with psoriasis before antitumor necrosis factor therapy: comparison of an interferongamma release assay vs tuberculin skin test. Br J Dermatol. 2009; 161:797-800.
90. Li S, Kaur PP, Chan V et al. Use of tissue necrosis factor-alpha antagonists infliximab, etanercept, adalimumab with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009; 28:787-91.
91. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006; 21:1366-71. (Pubitemid 44154702)
92. Paradisi A, Caldarola G, Capizzi R et al. Safety of etanercept in patients with psoriasis and hepatitis C assessed by liver histopathology: preliminary data. J Am Acad Dermatol. 2010; 62:1067-9
93. Magliocco MA, Gottlieb AB. Etanercept therapy with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004; 51:580-4. (Pubitemid 39278078)
94. Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/13 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008; 7: 796-804.
95. Patel RV, Clark LN, Lebwohl M et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009; 60:1001-17.
96. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin and biologics: facts and controversies. Clin Dermatol. 2010; 28:88-92.
97. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 2009; 22:418-30.
98. Gelfand JM, Shin DB, Niemann AL et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006; 126:2194-201. (Pubitemid 44413165)
99. Weins A, Venson R, Correr CJ et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30:339-53.
100. Rozenblitt M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009; 22:56-60.
101. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010; 160:810-20.
102. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new tumor necrosis alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four week efficacy and safety results in a randomized, placebocontrolled study. Arthritis Rheum. 2009; 60:976-86.
103. Bissionette R, Langley RG, Papp K et al. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebocontrolled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res. 2009; 301:429-42.
104. Langley RG, Papp K, Bissionette R et al. Safety profile of intravenous and subcutaneous siplizumab, an ant-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol. 2010; 49:818-28.
105. Kimball AB, Gordon KB, Langley RG et al. The safety and efficacy of ABT-784, a fully human interleukin 12/23 monoclonal antibody in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol. 2008; 144:200-7. (Pubitemid 351287002)
106. Schafer PH, Parton A, Gandhi AK et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model for psoriasis. Br J Pharmacol. 2010; 159:842-55.